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Abstract
Cell death results in tissue damage and ultimately donor graft rejection and can occur as an
active molecular process through apoptotic, necrotic and newly identified Receptor
Interacting Protein 1 and 3 kinase (RIPK1/3) mediated necroptotic pathways. Necroptosis
leads to the release of inflammatory molecules and activation of immune cells which can
potentially threaten the graft and has yet to be studied in cardiac transplantation. We have
found that necroptosis was induced in murine cardiac microvascular endothelial cells
(MVEC) under anti-apoptotic conditions following TNFα treatment and results in the release
of the danger molecule high mobility group box 1 (HMGB1). Necroptosis was inhibited by
the RIPK1 inhibiting molecule necrostatin-1 and by genetic deletion of RIPK3. In addition,
tissue necrosis, release of HMGB1 and graft cell infiltrate were attenuated in RIPK3 null
heart allografts following transplantation. Finally, a brief sirolimus treatment markedly
prolonged RIPK3 null cardiac allograft survival in allogeneic BALB/c recipients as
compared to wildtype C57BL/6 donor grafts (95+5.8 vs. 24+2.6 days, P<0.05). This study
has demonstrated that RIPK1/3 contributes to MVEC death and cardiac allograft survival
through necroptotic death and the release of danger molecules. Our results suggest that
targeting RIPK-mediated necroptosis may be an important therapeutic strategy in
transplantation.
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Chapter 1

1
1.1

Introduction
Current status of cardiac allograft transplantation

Following irreversible cardiac damage, transplantation is the most beneficial and highly
pursued treatment option available. Cardiac transplantation is most commonly used to
treat diseases related to cardiomyocyte dysfunction, coronary artery disease, congenital
defects and valvular dysfunction1. In past decades, advances in therapeutic
immunosuppression and biopsy techniques have allowed adequate control of host
immune cell-mediated rejection, improving heart allograft half-life times from 9.6 years
in 1982-1992, to 12.0 years in 1993-20031. However, following 2003, improvements in
heart transplant survivability have been the result of enhanced one-year survival due to
superior therapeutic management of acute rejection, rather than novel chronic rejection
therapy, as indicated by conditional post-one-year survival rates1. The understanding of
the mechanisms involved in chronic rejection of heart allografts continues to fall behind
that of acute rejection, necessitating further research in the chronic rejection field.

1.2 Cardiac allograft rejection
Transplantation invariably results in organ injury mediated by host immune cell
activation and graft infiltration. Nearly every branch of the immune system has been
implicated in allograft rejection, including innate immunity2, 3, antibody mediated
rejection (AMR) resulting in hyperacute accelerated graft rejection and chronic
rejection4, and alloimmune recognition of donor MHC/HLA resulting in adaptive
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immune responses. Each of these branches poses a threat to the graft independently and
collectively.

Acute cellular rejection (ACR) in cardiac grafts is predominantly a T-cell mediated
response characterized by the infiltration of lymphocytes and macrophages into the graft
followed by myocyte necrosis and eventual loss of graft function. Host immune cell
infiltration can be focal or diffuse depending on the rejection grade defined by the
International Society of Heart and Lung Transplantation (ISHLT). ISHLT grading spans
from Grade 1, characterized by perivascular or interstitial infiltration with up to one focus
of myocyte damage, to Grade 4, characterized by diffuse polymorphous infiltrate with
extensive myocyte damage, edema, hemorrhage and vasculitis5, 6. According to the
current models of ACR pathogenesis, ACR is initiated by the maturation of recipient
CD4+ T helper cells, CD8+ cytotoxic T cells and the transformation of host B
lymphocytes into antibody producing plasma cells. These cell types can attack the graft
directly or indirectly through inflammatory responses that involve monocytes and
macrophages. This process is orchestrated by soluble cytokines, such as Tumor Necrosis
Factor α (TNFα)7, that can activate host immune cells or initiate cell death in target cells.
Clinically, over 60% of patients will experience one or more acute rejection episodes
within 6 months of transplantation. However, due to the advancement of biopsy
techniques and immunosuppressive management, acute rejection survival rates have
drastically improved1.
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In contrast to ACR, chronic cardiac allograft rejection presents as severe, diffuse vascular
intimal hyperplasia involving the entire vessel wall, often resulting in compromised
vascular flow and eventual ischemia, similar to non-transplant atherosclerosis. This
phenomenon is known as Graft Vascular Disease (GVD). Although the pathogenesis of
GVD is not fully understood, the process is known to be mediated by the diffuse
accumulation of smooth muscle cells within the vessel intima in response to vascular
damage. In the early stages of developing GVD lesions, subendothelial accumulation of
mononuclear inflammation occurs in conjunction with increased markers of endothelial
cell (EC) activation8, 9. As a result of low-level injury caused by recipient infiltrate, host
immune cells as well as dysfunctional graft endothelial and smooth muscle cells secrete
growth factors to recruit and activate smooth muscle cells8, 10, 11. Interestingly, the
mechanism of vascular damage seems to be irrelevant in the progression of GVD. Indeed,
non-immune graft injury such as IRI can exacerbate GVD through endothelial necrosis,
resulting in danger molecule release12 and EC activation9, 13, 14. Interestingly, intimal
thickening does not cross the suture line between graft and host vessels, implying an
alloimmune role also exists in the pathogenesis of GVD. CD4+ T cells have been
indirectly implicated in the progression of GVD through the disruption of nitrous oxide
production in ECs by interferon γ (IFNγ) release15 and cytokine/chemokine regulation by
TNFα16 after activation by antigen presenting cells (APC). Although it is unlikely that
any single mechanism causes GVD, the incidence of GVD correlates with CD4+ T cell
presence with indirect antidonor allospecificity17, suggesting that indirect allorecognition
is the major pathway of GVD development18. In contrast with ACR, GVD is
unresponsive to immunosuppressive treatment due to the plethora of biological
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mechanisms resulting in its pathogenesis. Consequently, GVD is currently the limiting
factor of cardiac allograft transplantation and future therapies, such as the one described
here, may instead rely on preventative treatment and endothelial preservation to extend
graft survival times.

Currently, several immunosuppressive methods exist to prevent cellular and antibody
mediated rejection. As mentioned, T cells often play a critical role during immune
responses against the allograft19. In order to achieve T cell activation, several molecular
pathways must be activated. These include antigen recognition through the T cell
receptor (TCR) (signal 1), verification by co-stimulators (signal 2), and cytokine
(particularly IL-2) induced proliferation and maturation. Many immunosuppressive
therapies target these pathways by preventing either APC activation or lymphocyte
activation and proliferation.

During immune reactions, T cells recognize foreign antigens presented on APCs using a
TCR/CD3 protein complex. To achieve T cell activation, survival and clonal expansion,
an additional signal, known as a costimulatory signal, must also be provided. Failure to
provide this signal will result in T cell anergy20. Several transplant-relevant costimulatory
receptors and ligands have been identified21. These include the CD28/B7 pathway and the
CD40/CD154 pathway. The CD28/B7 costimulatory pathway is one of the most
important T cell activation pathways in both mice and humans and activation failure of
this pathway results in T cell anergy, rendering T cells functionally inactive22, 23. Upon
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engagement with its ligands B7.1 (CD80) and B7.2 (CD86), CD28 initiates a T cell
activation signal, allowing for T cell survival, proliferation and cytokine production. This
activation pathway is negatively regulated by the CD28 analog cytotoxic T-lymphocyteassociated-antigen 4 (CTLA4), which is also expressed on the surface of T cells. CTLA4
binds B7.1 and B7.2 with greater affinity than CD28 and down-regulates T cell
responses24, 25 and knockout of either CTLA4 or CD28 results in severe
lymphoproliferative disorders. Blockade of CD28 directly results in unwanted clinical
side effects and therefore an antibody fusion protein CTLA4Ig is instead used to inhibit
CD28 activation26. Another important costimulatory pathway involves CD40 and CD154
interaction. CD40 is a TNFR superfamily member and is expressed on the surface of
APCs. Binding of CD154 on T cells to CD40 is critical for dendritic cell (DC) activation
and upregulation of MHC, B7 molecules and cytokine production27. CD40/CD154
activation is important during plasma cell isotype switching28, and indirect activation of T
cells through the promotion of CD80 or CD86 expression29. This pathway can be
inhibited using an anti-CD40 antibody, preventing CD40/CD154 binding, and has shown
efficacy in extending allograft survival but not in preventing GVD30.

Lastly, T cell specific immunosuppression can be achieved by inhibiting IL-2 cytokine
production. The advent of the calcineurin inhibitors cyclosporine and tacrolimus, which
bind cytosolic proteins cyclophilin and FK binding protein 12 (FKBP12) respectively,
greatly advanced the field of transplantation in the 1980’s. Binding of cyclophilin and
FKBP12 inhibits calcineurin phosphatase, preventing transcription of cytokines
(including IL-2) and T cell expansion. Sirolimus, which has a similar molecular structure
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to tacrolimus, also binds to FKBP12 but does not inhibit calcineurin phosphatase.
Instead, sirolimus binds to the mammalian target of rapamycin (mTOR), a downstream
effector of both the CD28/B7 costimulatory pathway and IL-2, effectively making
sirolimus an inhibitor of both signal 2 and signal 331. In this study, both sirolimus and
CD40 costimulatory blockade are used to promote allograft tolerance.

1.3 Immunophysiology of endothelial cells in transplantation
Microvascular endothelial cells (MVEC) are the first barrier between the graft and host
after any solid organ transplantation. Consequently, MVECs are a key player during graft
recognition by host immune cells and organ rejection. MVEC activation has been shown
to be an important factor in transplantation and can result from donor brain death32,
ischemia reperfusion injury (IRI)33, 34, cyclosporine toxicity35 and, most importantly, host
immune responses to donor antigens.

Following their activation, MVECs mediate graft injury directly or indirectly through
platelet adhesion, increased vascular permeability, expression of adhesion molecules and
the release of proinflammatory molecules, such as TNFα or interleukin 1 (IL-1), leading
to a loss of vascular integrity and enhanced tissue damage36. These mechanisms may
provide the first trigger of graft injury, resulting in increased host immune infiltration and
accelerated graft rejection.
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Interestingly, cultured human MVECs have been shown to cause direct activation and
proliferation of T cells in the absence of professional APCs through the expression of
active costimulatory molecules such as CD4037 and promote the differentiation of
monocytes into competent APCs38. Activation of CD4+ T cells induces expression of
HLA class-II molecules on MVECs through IFNγ production, eliciting a sustained
alloimmune reaction39 similar to delayed-type hypersensitivity reactions. MVECs also
contribute to GVD and smooth muscle cell recruitment both directly and indirectly.
Expression of intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1) and the E and P-selectins on MVECs has been directly correlated
to rejection and GVD40, 41 as expression of these molecules allows for adhesion and
rolling of host leukocytes on the EC barrier of the graft. Lastly, as previously mentioned,
EC dysfunction can exacerbate GVD through growth factor and danger molecule release.
As the first biological barrier between graft and host and a key mediator of lymphocyte
activation, ECs play an important role in alloimmune responses following cardiac
transplantation.
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Figure 1 – Anatomy of an artery
An artery consists of several anatomical structures including the endothelium, intimal
region, smooth muscle layer and is surrounded by connective tissue. The endothelial
layer interacts with blood cells in the serum and plays important roles in facilitating white
cell emigration from the blood into the tissue. In transplantation, the endothelial lining
serves as the barrier between the graft and the host, making it an important player in
immune responses against the graft.
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1.4 TNFα and TNFα receptors
TNFα, also known as cachectin, was originally identified as a potent inducer of cell death
in tumour cells42 but is recognized today as a pleotropic cytokine involved in many signal
transduction pathways including cell survival, proliferation, activation and cell death.
TNFα has been shown to be an important contributor to heart graft rejection and GVD
through the regulation of soluble TNFα43 and TNFα receptors44. Furthermore, TNFα has
implicated in the induction of early neutrophil and macrophage chemoattractant levels,
increased immune cell infiltrate45 and decreased graft survivability46, 47 following cardiac
transplantation.

As suggested above, TNFα can induce a variety of cellular responses. Traditionally,
TNFα was thought to induce programmed apoptosis in target cells following TNFα
Receptor (TNFR) 1 binding, or immune activation through transcription factor NF-κB
following TNFR2 signalling7. Interestingly, human and murine MVECs in heart grafts
constitutively express diffuse levels of death receptor TNFR1 and activating receptor
TNFR2 before and after transplantation48. Conversely, cardiomyoctytes, which normally
express high levels of TNFR1, drastically reverse TNFα receptor expression from
TNFR1 to TNFR2 following rejection injury44, 48. This suggests that human and murine
MVECs in donor grafts may be more vulnerable to TNFα mediated death than
cardiomyocytes. Recently, TNFα has been shown to also initiate a second cell death
pathway known as necroptosis, also initiated through TNFR149, 50.
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1.5 Apoptosis, necrosis and necroptosis
Cell death has been classified into a variety of forms including apoptosis, necrosis, postapoptotic secondary necrosis, necroptosis, autophagy and mitotic catastrophe51. The two
extremes in the array of cell death are caspase-dependent apoptosis and caspaseindependent necrosis. Apoptosis is characterized by DNA fragmentation and membrane
blebbing induced by endogenous nucleases, whereas necrosis is characterized by swelling
of the mitochondria and cytoplasm, due to ATP depletion, leading to eventual plasma
membrane rupture and lysis of the cell.

Traditionally, apoptosis was viewed as the primary active and programmed form of cell
death while necrosis was viewed as a passive and immunogenic form of cell death.
However, this paradigm has been challenged in recent years with the discovery of
necroptotic cell death, which takes on characteristics of both apoptosis and necrosis. Like
apoptosis, necroptosis requires endogenous cellular machinery to initiate cell death. This
process is initiated through either TNFR149, tumour necrosis factor-related apoptosisinducing ligand (TRAIL)52, 53, Fas54, Toll-like receptor (TLR) 355 or 456, or retinoic acidinducible protein57 signalling. The result is the activation of receptor interacting protein
kinase (RIPK) 1 and RIPK3, together known as the necrosome, which induce necroticlike cell death through endogenous reactive oxygen species (ROS) production.

TNFα mediated death signalling requires the formation of a complex of proteins on the
inner membrane domain of TNFR1 known as Complex I (Figure 1). This complex
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includes TNFα receptor associated death domain (TRADD), TNFα receptor associated
factor (TRAF), cellular inhibitors of apoptosis (cIAP) 1 and 2, and poly-ubiquitinated
RIPK1. Binding of NF-kappa B essential modulator (NEMO) to the ubiquitin tail of
RIPK1 will result in the downstream activation of NF-κB, mitogen-activated protein
kinase (MAPK) and c-Jun N-terminal kinases (JNK), resulting in survival of the cell.
Alternatively, deubituitination of RIPK1 by enzymes A20 or cylindromatosis (CYLD)
will result in formation of complex II, which includes RIPK1, RIPK3, TRADD and the
Fas Associated Death Domain (FADD)58-60. Caspase-8 recruitment into Complex II will
result in the cleavage of RIPK1 and RIPK3 followed by caspase-8 mediated apoptosis. In
the absence or inhibition of caspase-8, RIPK3 will autophosphorylate itself and
phosphorylate RIPK1, initiating a downstream cascade resulting in up-regulation and
activation of three metabolic enzymes: Glutamine Synthase (GLUL), Glutamate
Dehydrogenase (GLUD1) and Glycogen Phosphorylase (PYGL)50, 60. PYGL is
responsible for the catabolism of glycogen to glucose-1-phosphate, directly fuelling
glycolysis, while GLUL catabolises glutamate to glutamine, stimulating gluconeogenesis,
glutathione production and lipogenesis. GLUD1 is subsequently involved in glutamine
catabolism, increasing the cellular pool of α-ketoglutarate to feed the TCA cycle. RIPK
mediated increases in cellular energy metabolism through activity of these enzymes
results in excessive reactive oxygen species (ROS) production within the mitochondria,
eventually resulting in cytotoxicity of the cell61. Indeed, mitochondrial derived ROS have
been implicated in the ultrastructural changes seen in cellular organelles during
programmed necrosis62. This provides strong evidence that the current model of TNFα
induced necroptosis is mediated through increased ROS production. Consequently, like
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traditional necrosis, necroptosis is considered to be immunogenic, potentially making it
an important player during transplantation.

1.6 Inhibiting TNFα mediated cell death
The discovery of TNFα mediated necroptosis lead to the discovery of chemical
compounds that allosterically inhibited the kinase activity of RIPK1, known as
necrostatins63, 64. These compounds do not affect the activation of NF-κB, MAPK or JNK
signalling following TNFR1 activation, confirming the bifurcation between cell survival
and cell death following TNFR1 activation. Necrostatins have been shown in
experimental models to be beneficial inhibitors of cell death following ischemic brain
injury63, myocardial infarction65 and chemotherapy-induced cell death66. Conversely,
because the induction of TNFα mediated necroptosis is dependent on caspase-8
inactivity, compounds that inhibit caspase-8, such as the pan-caspase inhibitor zVADfmk, can be used to induce necroptosis following TNFα treatment60. zVAD-fmk works
by binding the active site of caspase-867, preventing caspase-8-ligand interactions.

Although synthetic caspase inhibitors such as zVAD-fmk do not exist in biological
systems, caspase inhibition can occur naturally in a variety of instances. In fact, simple
changes in the redox status of the active cysteine residue in the caspase active site can
render caspase activation impossible68. A study by Cho and colleagues has also revealed
that TNFα treated cells infected with vaccinia virus, which encodes the viral caspase
inhibitor Spi2, also undergo necroptosis and knockout of RIPK3 in this model results in
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higher vaccinia virus titers compared with wildtype mice69. This data implies that RIPK
signalling likely has a physiological role as a backup mechanism in viral protection
where the viral target is caspase-8. This protective effect is then amplified by the release
of cellular danger associated molecular patterns (CDAMPS) following necroptosis, which
attract and activate the innate and adaptive immune system70. Interestingly, it seems that
some viruses, such as cytomegalovirus (CMV), have evolved to escape this mechanism.
CMV does this through expression of viral proteins M36, an inhibitor of caspase-8
activation71, and M45, an adaptor protein that interferes with RIPK1 and RIPK3
interaction72 and NF-κB activation73, rendering TNFR1 signaling inert. Physiologically,
necroptosis appears to be another player in the biological arms race between infecting
organisms and the immune system.
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Figure 2 – The mechanism of TNFα mediated necroptosis
TNFα initiates necroptosis through binding of TNFR1. Following this, an intracellular
complex forms on the innermembrane domain of the TNFR1 receptor, including
polyubiquitilylated RIPK1. Binding of NEMO to the ubiquitin tail of RIPK1 results in a
downstream pathway activating NFκB. Alternatively, enzymes A20 or CYLD
deubiuinate RIPK1, which associates with RIPK3 to form the necrosome. Caspase 8, if
present, will cleave the necrosome and initiate caspase-dependent apoptosis. If caspase 8
is absent or inhibited, the necrosome will autophosphorylate and activate downstream
enzymes, initiating necroptosis.
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1.7 Inflammatory implications of cell death
Apoptotic death prevents the release of cell contents and can minimize inflammation,
whereas necrosis results in the release of pro-inflammatory CDAMPs, including high
mobility group box 1 (HMGB1), heat shock protein (HSP), RNA, DNA, fibronectin, and
uric acid74, 75. These released danger molecules promote inflammatory responses through
interactions with TLRs and other innate receptors74-76. In transplantation, TLR
engagement has been found to accelerate vascular allograft rejection77-79, making
proinflammatory CDAMPs such as HMGB1, which are only released following cell
lysis, a powerful marker for necroptosis75. Indeed, necroptosis has been implicated in a
variety of diseases resulting in CDAMP release including cerulean-induced pancreatitis60,
80

, cerebral cortex infarction63, chronic intestinal inflammation81, systematic

inflammatory response syndrome82, myocardial infarction65, 83 and IRI in the kidney84, 85
and heart86, 87. Distinguishing these mechanisms of cell death could be crucial in
transplantation as necroptosis is phenotypically similar to necrosis and may play a central
role in allograft rejection by enhancing the release of proinflammatory danger molecules
and promoting inflammatory injury in the graft.
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Figure 3 – HMGB1 release following necrotic cell death
HMGB1, a nuclear protein involved in chromatin architecture, is a potent immunogenic
CDAMP. During apoptosis, HMGB1 is oxidized and sequestered to the nucleus where it
is rendered inactive. However, during necrosis or necroptosis, active HMGB1 is released
from the cell where it will interact with TLRs and RAGE receptors on immune cells,
initiating an immune response.
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1.8 Hypothesis
We hypothesize that the pattern of cell death in the graft following cardiac transplantation
affects graft survivability as necrotic or necroptotic death will lead to exacerbated
inflammation and accelerated graft rejection.

Figure 4 – Necrostatin-1 or RIPK3 knockout will prevent exacerbation of
inflammation
Following cardiac transplantation, inflammation will lead to graft immune cell infiltration
and the release of TNFα. In wild type mice, heart cells will be susceptible to
RIPK1/RIPK3 mediated necroptosis, which leads to the release of the immunogenic
CDAMP HMGB1. This in turn leads to the activation of more host immune cells and
further inflammation. Treatment with Nec-1 or knockout of RIPK3 prevents cells from
undergoing RIPK1/RIPK3 mediated necroptosis, breaking the inflammatory cycle.
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1.9 Specific aims
1. To determine the effects of apoptosis and necroptosis on MVECs.
2. To show that the inhibition of RIPK1 and RIPK3 function in MVECs results in
decreased necroptotic death and subsequent danger molecule HMGB1 release.
3. To determine if RIPK3 deficiency in donor heart grafts inhibits necroptosis and
subsequently prolongs graft survival.
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Chapter 2

2

Materials and Methods

2.1 Animals
C57BL/6 (H-2b), BALB/c (H-2d) (Jackson Laboratories, Bar Harbor, ME), and B6
RIPK3-/- mice (H-2b) (Genentech)88 were maintained in the animal facility at the Western
University. All experimental procedures were approved by the Western University
Animal Care Committee.

2.2 Microvascular endothelial cell (MVEC) culture
MVECs from mice hearts were isolated as previously described89 using anti-CD31 coated
Dynal magnet beads (Invitrogen). MVECs were immortalized through transfection of
origin-defective SV40 DNA90. Transfection was done using the calcium-phosphate coprecipitation method (Invitrogen). Cells were grown in complete EGM-2 MV containing
5% FBS, 0.04% hydrocortisone, 0.4% hFGF-b, 0.1% VEGF, 0.1% R3-IFG-1, 0.1%
Ascorbic acid, 0.1% hEGF and 0.1% GA-1000 (Lonza). MVEC phenotype was
confirmed by staining with anti-CD31, CD102 and CD105 (eBioscience). Cells were
passaged a maximum of 10 times before being discarded.

2.3 Heart transplantation
BALB/c mice (H-2d) were transplanted with heterotopic hearts from either C57BL/6 or
B6 RIPK3-/- (H-2b) mice. Ischemic time was limited to 15 minutes during all
transplantations. The donor heart was anastomosed via the donor aorta to the recipient
abdominal aorta and donor pulmonary artery to recipient inferior vena cava using
microsurgical techniques. The donor vena cava and pulmonary vein were sutured shut.
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Following reperfusion, the heart grafts resumed spontaneous contraction. Recipients were
treated daily with 1mg/kg sirolimus (LC Laboratories, Woburn, MA) from day 0 until
postoperative day 991 or CD154 antibody (MR1) (200ug) one preoperative day before
transplantation. The strength and quality of cardiac muscle contractions were monitored
by palpation of the abdomen. Graft rejection (cessation of pulsation) was monitored daily
after transplantation and confirmed by pathological analysis.

2.4 In situ ethidium homodimer perfusion
Recipient animals were anesthetized with the mixture ketamine/xylazine according to the
approved animal protocol. The abdominal cavity was opened and the heterotopic heart
was isolated from surrounding tissue. A blood sample was taken from the inferior vena
cava above the left renal vein at this time. The inferior vena cava and dorsal aorta were
then fully occluded just above and below the heterotopic heart using a microsurgical
vascular clamp. The pulmonary artery of the donor heart was then cut to allow the
perfusion solution to drain. A solution of 5 µM ethidium homodimer (Invitrogen) in
saline was perfused into the aorta at 1 ml/min for 5 minutes92. Successful perfusion was
observed by flushing of blood from the descending coronary arteries, expansion of the
heterotopic heart and exit of perfusion solution from the pulmonary artery incision.
Following this, saline was perfused at 1ml/min for 10 mins to flush excess and unbound
ethidium homodimer. The heart was then removed and cut through the transverse plane
before being put in formalin or liquid nitrogen.
Tissues were analyzed and quantified for area and fluorescent intensity by a fluorescent
microscope (NIS Elements 3.0, Nikon). Areas positive for necrosis were measured by
ethidium homodimer labelled red fluorescence.
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2.5 Western blot
Supernatants were collected from equal number cell seeded wells for western blot
analysis. Protein was isolated from heart tissue using cytoplasmic lysis buffer (10mM
HEPES, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 0.1%NP40, 1mM DTT, 0.5mM
PMSF) for non-nucleic protein analysis. Protein concentration was determined using BioRad Protein Assay (Bio-Rad) at 595nm on a spectrophotometer (Beckman Coulter).
Sample buffer (2ME, glycerol, bromophenol blue, Tris-HCl) was added to the protein
and was separated by gel electrophoresis by 4% resolving gel and 10% running gel.
Protein was transferred to a nitrocellulose membrane using the iBlot dry transfer system
(Invitrogen). Blots were blocked with 5% milk (Carnation) in Tris buffered saline and
Tween 20 (TBS-T) and were incubated with polyclonal rabbit anti-RIPK3 (Abcam),
rabbit anti-HMGB1 (Abcam), or mouse anti-β-actin (Sigma) in 2.5% milk TBS-T.
Protein was visualized using secondary anti-rabbit IgG (Sigma) antibody with conjugated
horseradish peroxidase and chemiluminescent HRP substrate (Millipore). Protein
concentration was semi-quantitated by densitometry (Alpha View) and normalized using
β-actin.

2.6 RNA isolation and real-time PCR
Total RNA was extracted from tissue or cells by Trizol extraction (Invitrogen). cDNA
was generated from RNA using Superscript II (Invitrogen). Primers used for real time
PCR include: RIPK3: 5’-GGGACCTCAAGCCCTCTAAC-3’ and 5’GATCCCTGATCCTGACCCTGA-3’. β-Actin: 5'-CCA GCC TTC CTT CCT GGG TA
and 3'-CTA GAA GCA TTT GCG GTG CA. Real-time quantitative PCR was performed
on standardized quantities of cDNA using the SYBR qPCR Master Mix kit (BioRad).
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Gene amplification was performed and detected using the Mx3005 system (Stratagene).
β-actin amplification was used as the endogenous control. The normalized delta threshold
cycle value and relative expression levels (2-∆∆Ct) were calculated according to the
manufacturer’s protocol.

2.7 Cell death assay
MVECs were grown to monolayer and treated with 100µg/ml of recombinant human
TNFα (Peprotech) and 60µg/ml recombinant mouse IFNγ (Peprotech), 60 µM zVAD-fmk
(BD Bioscience) and/or 10 µM necrostatin-1(Calbiochem) in serum free media for 48h.
MVECs were trypsinized (Gibco) and washed with PBS. Cell death was detected with
propidium iodide (P.I.) or annexin V labeling (BD Bioscience) and analyzed by flow
cytometry (Beckman Coulter).

2.8 Histology and immunohistochemistry
Tissue sections were stored in 5% formalin (Sigma) and paraffin fixed and stained with
hematoxylin and eosin (H&E). Slides were scored by a pathologist in a blinded fashion
(0: no change, 1+: <25% area change, 2+: 25-50% area change, 3+: 50-75% area change,
4+: 75% area change)91, 93. Criteria for allograft injury included endothelial cell damage,
infarction, lymphocyte infiltrate, fibrosis, thrombosis, hemorrhage, myocyte damage and
neutrophil infiltrate.
RIPK3 and HMGB1 expression in the heart graft was detected by anti-RIPK3 (Abcam)
or anti-HMGB1 (Abcam) by immunohistochemistry according to a standard protocol.
Apoptosis in tissue was determined by TUNEL staining (Calbiochem).
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2.9 Statistical analysis
Data was compared using Student’s t-test for unpaired values. Graft survival was
analyzed by log-rank testing (Mantel-Cox). Data was presented as mean ± standard
deviation (SD) and p values < 0.05 were considered to be significantly different.

25

Chapter 3

3

Results

3.1 Isolation and characterization of MVECs
MVECs were developed from C57BL/6 hearts as described in the methods. The
phenotype of MVECs was confirmed by morphology (Figure 5A) and flow cytometry
through CD3194, CD10295, and CD10596 positivity (Figure 5B).
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Figure 5 – Isolation and characterization of MVECs
A) MVECs were isolated using CD31 coated beads and immortalized with
origin deficient SV40 DNA. Cells were grown in a monolayer analysed using
confocal microscopy at 400X magnification. B) Cells were also analysed for
the presence of the endothelial markers CD31, CD102 and CD105 by flow
cytometry analysis.
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3.2 RIPK3 and TNFR1 expression in MBECs are regulated
by proinflammatory cytokines
We first determined whether TNFR1 and RIPK3 expression can be regulated by
proinflammatory cytokines in MVECs as TNFα mediated apoptotic or necroptotic cell
death requires expression of death receptor TNFR1 and RIPK3. Expression of RIPK3 in
MVECs was analyzed by qPCR after treatment with TNFα or IFNγ. Our data indicates
that treatment with TNFα up-regulates RIPK3 mRNA expression in a dose dependant
manner (Figure 6A). Significant differences were seen at treatments of 25ng/ml
(mean+SD: 2.7 + 0.2 fold change, n=3, p<0.01) and 50 ng/ml of TNFα (12.5 + 1.6 fold
change, n=3, p<0.05) compared to untreated MVECs. Expression of RIPK3 in MVECs
was confirmed by western blot analysis (Figure 6B).

Surface expression of TNFR1 on MVECs was determined by FACS analysis. As shown
in Figure 6C, expression levels of TNFR1 on MVECs can be modulated by TNFα or
IFNγ with maximum upregulation at 60ng/ml TNFα or IFNγ. Hence, proinflammatory
cytokines can upregulate both TNFR1 and RIPK3 expression in MVECs.
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Figure 6 - Expression of RIPK3 and TNFR1 in microvascular endothelial cells
are upregulated by proinflammatory cytokines

MVECs were isolated as described in the methods. A) MVECs were treated
with 0, 25, 50 or 100 ng/ml TNFα for 48 hours in serum free EBM media.
RIPK3 expressions were measured by real time qPCR as described in the
methods. Β-actin was used as control (n=3, *: p < 0.05). B) RIPK3 protein was
detected by western blot by anti-RIPK3 (Abcam) after 48 hour treatment with
TNFα. C) Cells were treated with either 60 ng/ml TNFα or 60ng/ml IFNγ.
Surface expression of TNFR1 on MVECs was measured using anti-TNFR1-PE
(eBioscience) and analyzed by flow cytometry.
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3.3 TNFα induces necroptosis in L929 cells under antiapoptotic conditions
As previously described, L929 mouse fibroblasts are extremely susceptible to necroptotic
death49. Before attempting to induce necroptosis in MVECs, L929 cells were treated with
TNFα, zVAD-fmk and necrostatin and cell death was determined by PI positivity. TNFα
can signal through either TNFR1 or TNFR2, initiating either cell death or cell survival
response, respectively97, 98. We therefore used human TNFα (hTNFα) to maximize
TNFR1-mediated cell death as hTNFα specifically initiates TNFR1, rather than TNFR2,
signalling on murine cells99. As seen in Figure 7, hTNFα (80ng/ml) + IFNγ (30ng/ml)
treatment increased PI positivity, not Annexin V positivity, compared with untreated
cells. The addition of (4uM) Nec-1 was able recover this PI positivity. Conversely, the
addition of (10uM) zVAD-fmk increased cell death substantially, which was again
recovered partially by Nec-1.
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Figure 7 – L929 cells undergo necroptotic cell death after TNFα treatment
L929 cells were treated with 80ng/ml hTNFα and 30 ng/ml IFNγ in the presence or
absence of 4uM Nec-1 and 10uM zVAD-fmk for 24 hours and cell death was
determined using Annexin V and PI staining on FLOW cytometry analysis.
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3.4 MVECs with RIPK1 inhibition are resistant to
necroptotic death
We next measured TNFα-induced necroptotic death in MVECs following treatment with
TNFα. TNFα can signal through either TNFR1 or TNFR2, initiating either a cell death or
cell survival response, respectively97, 98. Again, hTNFα was used to induce cell death. As
shown in Figure 8A&B, we observed that MVECs treated with hTNFα (100ng/mL) +
IFNγ (60ng/mL) increased cell death compared with untreated cells (PI positivity: 19.3 +
2.1% in TNFα treated vs 9.4 + 1.6% in untreated cells, n=3, p=0.01). In order to
modulate necroptotic death, the RIPK1 inhibitor necrostatin-1 (Nec-1) (10uM), and pancaspase inhibitor zVAD-fmk (60uM) were used. Addition of Nec-1 to hTNFα treatment
reduced cell death to 12.5 + 5.1% PI positive (Figure 8A&B, n=3, p=0.09). However,
zVAD-fmk+hTNFα treatment increased PI positivity to 25.9 + 2.7% (n=3, p=0.001),
suggesting that increased PI positive cell death occurs only after the inhibition of
caspases. Furthermore, zVAD-fmk induced cell death could be reversed by addition of
the RIPK1 inhibitor Nec-1 (15.6 + 2.0%, n=3, p=0.02, Figure 8A&B), providing further
evidence that a RIPK-mediated cell-death response occurs when caspase-mediated
apoptotic pathways are blocked. These results suggest that MVECs are able to undergo
TNFα induced cell death, which can be modulated by the inhibition of RIPK1.

To further illustrate that the RIPK proteins regulate necroptosis and HMGB1 release,
RIPK3 deficient MVECs were isolated from RIPK3-/- mice and treated with hTNFα and
zVAD-fmk. PI positivity did not increase significantly following hTNFα treatment alone
(6.5 + 3.0%, vs 7.3 + 2.3% in untreated cells, n=3, p=0.39) or after hTNFα treatment with
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zVAD-fmk (7.5 + 1.1%, n=3, p=0.27, Figure 8C), suggesting that TNFR1 signaling
cannot induce necroptosis following the deletion of RIPK3.

36

A
Unstained

TNFα/IFNγ

Untreated

nec-1/TNFα/IFNγ

nec-1

zVAD/ TNFα/IFNγ

zVAD-fmk

nec-1/zVAD/TNFα/IFNγ

B

% PI Positive

Wildtype MVECs
4
*
*
3
2
1
0

*

37

C
15

% PI

10

5

0

RIPK3-/- MVECs

38

Figure 8 - RIPK1 and RIPK3 regulates necroptosis in MVECs

MVECs from C57BL/6 wild type mice or RIPK3-/- mice were plated in equal
numbers (105) and treated with 100ng/ml TNFα, 60uM zVAD-fmk or 10uM
Nec-1 in serum free media. A) C57BL/6 MVECs death was measured by PI
positivity after 48 hours using flow cytometry analysis. Histograms are
representative of three experiments. B) Quantitated average of three
independent cell death experiments from C57BL/6 MVECs (n=3, *: p < 0.05,
**: p < 0.01). C). Quantitated average of three independent cell death
experiments from RIPK3-/- MVECs (n=3, p > 0.05).
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3.5 SMAC mimetics exacerbate TNFα mediated
necroptosis
Upon signaling TNFR1, TNFα can initiate either a cell survival or cell death response61.
In an attempt to abrogate the pro-survival pathway following TNFR1 signaling, cIAP
inhibiting SMAC mimetics were used to prevent up-regulation of NF-κB genes through
the prevention of protein translation100. As seen in Figure 9, treatment with SMAC
mimetic (100nM) + hTNFα (100ng/mL) increased the PI quadrants after just 6 hours.
Addition of Nec-1 attenuated PI positive cell death, however, zVAD-fmk (10uM) was not
able to exacerbate PI positivity, likely due to the low concentration added.
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Figure 9 – SMAC mimetic exacerbates TNFα mediated necroptosis
Wild type MVECs were plated in equal numbers (105) and treated with SMAC Mimetic
(100nM), hTNFα (60ng/mL) in the presence and absence of Nec-1 (10uM) and zVADfmk (50uM) and cell death was analysed using Annexin V and PI labeled flow
cytometry analysis.
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3.6 RIPK3 null MVECs are resistant to apoptotic and
necroptotic death
Since we were previously unsuccessful in initiating a cell death response in RIPK3-/MVECs, we suspected that the removal of the necroptotic pathway may be preferentially
initiating apoptosis, rather than necrosis after TNFα treatment. To test this, cells were
treated with TNFα in the presence and absence of zVAD-fmk and stained with both
Annexin V and PI. As seen in Figure 10A, RIPK3-/- cells treated with 100ng/mL hTNFα
did not undergo significant increases in Annexin V positive or PI positive cell death, even
after treatment with zVAD-fmk (60uM). However, super-physiological addition of
600ng/mL hTNFα induced significant Annexin V positivity with no change in PI
positivity, indicating an apoptotic response. This response could subsequently be
recovered with the addition of zVAD-fmk (60uM), as seen in Figure 10B. These data
indicate that RIPK3 null MVECs are indeed resistant to TNFα mediated necroptosis and
preferentially undergo apoptosis after treatment with super-physiological amounts of
hTNFα, which can be recovered with zVAD-fmk, a caspase-8 inhibitor.
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Figure 10 – RIPK3-/- MVECs are resistant to apoptotic and nectoptotic cell death
MVECs from RIPK3-/- wild type mice were plated in equal numbers (105) and treated
with A) 100ng/ml TNFα, 60uM zVAD-fmk or 10uM Nec-1 in serum free media or B)
600ng/ml TNFα, 60uM zVAD-fmk or 10uM Nec-1 in serum free media and cell death
was measured by Annexin V and PI positivity after 48 hours using flow cytometry
analysis.
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3.7 RIPK1 inhibition or RIPK3 deficiency prevents to
danger molecule HMGB1 release in MVECs
Cells undergoing necrosis, not apoptosis or late apoptosis, release proinflammatory
CDAMPs such as HMGB174, 101. We therefore measured cell-released HMGB1 in the
supernatant of MVECs treated with hTNFα (100ng/mL) + IFNγ (60ng/mL) in the
presence and absence of Nec-1 (10uM) or zVAD-fmk (60uM) using western blot analysis
to confirm our findings in PI labelling cell death assays to verify the presence of necrotic
cells. As expected, release of HMGB1 in TNFα treated MVECs correlated with the
necroptotic pattern of cell death. Following treatment with zVAD-fmk and TNFα,
HMGB1 release in MVEC supernatant increased significantly (band density: 8.33+3.61
vs. 1 in untreated, n=4, p=0.02, Figure 11A&B). Addition of Nec-1 was able to attenuate
HMGB1 release under anti-apoptotic conditions (intensity index 2.43+1.22, n=4, p=0.03,
Figure 11A&B). These results indicate that HMGB1 release follows RIPK1 mediated
necroptotic MVEC cell death.

Similarly, there were no significant levels of HMGB1 detected in the supernatant of
untreated RIPK3-/- cells and this remained unchanged following TNFα and zVAD-fmk
treatment (Figure 11A). Therefore, RIPK3 deficiency, similar to RIPK1 inhibition, in
MVECs also prevents TNFα induced-necroptotic death and HMGB1 release.
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Figure 11 – RIPK1 and RIPK3 regulate HMGB1 release in MVECs
MVECs from C57BL/6 wild type mice or RIPK3-/- mice were plated in equal
numbers (105) and treated with 100 ng/ml TNFα, 60mM zVAD-fmk or
10mM Nec-1 in serum free media for 48 hours. (A) Supernatants collected
from treated C57BL/6 MVECs and RIPK3-/- MVECs were analyzed for
HMGB1 release by western blot. Equal volumes of supernatants were loaded
for each treatment. As loading controls, remained C57BL/6 MVECs and
RIPK3-/- MVECs were collected and the cytoplasmic lysates were used for
detected the unreleased HMGB1 inside MVECs. (B) Western blot results
were quantitated by densitometry analysis (Alpha View). Untreated MVECs
were use as a reference. Quantitated average of three independent cell death
experiments (n=3, *: p < 0.05).
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3.8 RIPK3 regulates heart graft necrosis and HMGB1
release after transplantation
RIPK1 and RIPK3 are integral for the formation of the necrosome which leads to
downstream necroptosis50, 60. However, knockout of RIPK1 in mice results in newborn
lethality and therefore no model involving RIPK1 knockout exists in vivo102. To further
investigate the effect of RIPK signalling in donor heart grafts, heterotopic heart
transplantations were performed using wildtype C57BL/6 or B6 RIPK3-/- mice as donors
and BALB/c mice as recipients. Recipient mice were given brief sirolimus treatment
from day 0-9 to prolong heart survival91 and were sacrificed 12 days after transplantation.
Upon sacrifice, heart grafts were collected for analysis of early tissue necrosis and
apoptosis. In situ ethidium homodimer perfusion was performed as described in the
methods to detect necrotic cells92. Heart grafts were examined for ethidium homodimer
labelled areas (red) for necrosis using fluorescence microscopy.

As seen in Figure 12A&B, H&E staining of wildtype and RIPK3-/- grafts showed
increased lymphocyte infiltration localized primarily around the vessels in wildtype grafts
compared with RIPK3-/- grafts (severity score: 3 + 0.6 in wildtype vs. 1.6 + 0.8 in RIPK3/-

heart, n=5, p=0.01). Ethidium homodimer staining revealed that wildtype heart grafts

had significantly higher levels of necrosis localized around the vessels of the heart
compared with RIPK3-/- grafts (intensity index: 157.1 + 106.2 in wildtype vs. 12.1 + 9.5
in RIPK3-/- heart, n=3, p=0.03) (Figure 12A&C), where staining was confined primarily
to the endothelial barrier. TUNEL staining was used to detect apoptotic cells in situ and
showed no significant differences between wildtype and RIPK3-/- heart grafts (5.5 + 5.7
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in wildtype vs 1.6 + 2.4 in RIPK3-/-, n=3, p=0.09) (Figure 12A&E), suggesting that
RIPK3 deficiency did not alter apoptosis in the graft compared with wild type mice.
RIPK3 deficiency in RIPK3-/- naïve hearts was confirmed by western blot analysis
(Figure 12D). In summary, these data suggests that RIPK3 deficiency protects heart
grafts from necrotic death and endothelial damage post transplantation.
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Figure 12 – RIPK3 deficiency reduces necrosis and graft infiltration following heart
transplantation
Wildtype C57BL/6 or B6 RIPK3-/- donor hearts were heterotopically transplanted into
BALB/c recipients. Sirolimus (1mg/kg) was given from operative day 0 to post-operative
day 9 and heart grafts were collected at post-operative day 12. A) Graft tissue obtained
was formalin fixed at the time of sacrifice and stained by H&E, ethidium homodimer or
TUNEL assay. Data is representative of five transplanted grafts. Areas of greatest injury
are shown in both wildtype and RIPK3-/- grafts. B) Blinded quantitative pathological
scoring of cellular infiltration in wildtype and RIPK3-/- grafts. Slides were scored on a
scale from 0-4 as described in the methods (n=5, *: p <0.05). C) Quantification of
ethidium homodimer fluorescence staining for necrosis in wildtype and RIPK3-/- heart
grafts 12 days following transplantation (n=3, *: p < 0.05). D) Quantification of TUNEL
staining for apoptosis in wildtype and RIPK3-/- heart grafts 12 days following
transplantation (n=3, ns: p>0.05). E) Western blot analysis of wildtype and RIPK3-/- heart
grafts for expression of RIPK3 protein.
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3.9 HMGB1 release is attenuated in RIPK3 null allografts
following cardiac transplantation
As mentioned previously, necrosis results in the release of proinflammatory HMGB174,
101

. Interestingly, HMGB1 released following necrotic cell death can exist in an

immunogenically active form, whereas cells undergoing apoptosis can release a tolerance
promoting (oxidized) form103. We therefore measured HMGB1 in heart graft lysates
isolated by cytoplasmic lysis buffer at day 12 following transplantation. Western blot
analysis revealed that only the active form of HMGB1 increased in wildtype grafts, but
not in RIPK3-/- grafts (Intensity index: 0.99 + 0.22 in wildtype vs. 0.64 + 0.19 in RIPK3-/, n=5, p=0.03, Figure 13A&B). Interestingly, the (lower) oxidized band of HMGB1
remained statistically similar between wildtype and RIPK3-/- grafts (0.34 + 0.19 in
wildtype vs. 0.35 + 0.13 in RIPK3-/-, n=5, p=0.12, Figure 13A&B).

Immunohistochemistry for HMGB1 revealed increased HMGB1 release from the nucleus
of cardiomyocytes surrounding the vessels (red arrows) in wildtype grafts compared with
RIPK3-/- grafts (Figure 13C). Released HMGB1 can be seen diffusely in the cytoplasm of
injured cells. Taken together, these data further support the notion that deficiency of
RIPK3 provides a protective role against necroptotic death and subsequent HMGB1
release in heart grafts.

Lastly, we measured the chemokine expression levels in wildtype and RIPK3 null grafts
12 days following transplantation, as shown in Figure 13D. Compared with naïve,
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untreated C57BL/6 hearts, wildtype grafts expressed higher transcript levels of CXCL10
(26.5 + 27.6 fold increase in wildtype vs 13.2 + 13.2 in RIPK3-/-, n=5, p=0.2), CCL3
(30.9 + 53.7 fold increase in wildtype vs 9.5 + 8.5 in RIPK3-/-, n=5, p=0.24),
RANTES(8.1 + 14.9 fold increase in wildtype vs 1.2 + 2.0 in RIPK3-/-, n=5, p=0.21) and
MCP-1 (31.3 + 55.1 fold increase in wildtype vs 1.63 + 1.8 in RIPK3-/-, n=5, p=0.17)
than RIPK3 null grafts. However, these differences were non-significant.

55

A

B

1.4

*

1.2

Intensity Index

1
0.8

Active HMGB1
0.6

Oxidized HMGB1

0.4
0.2
0

Wildtype

RIPK3-/-

56

C

Wildtype

RIPK3-/-

Naïve

Day 12

D
100
90

70

mRNA

Fold Increase of

80

60
50

Wildtype

40

RIPK3-/-

30
20
10
0
CXCL10

CCL3

RANTES

MCP1

57

Figure 13 – RIPK3 deficiency inhibits danger molecule HMGB1 release and
inflammatory responses in the heart graft
Protein from heart grafts collected 12 days following heart transplantation as
described in Figure 12 were isolated by cytoplasmic lysis buffer before being
examined for HMGB1. A) Western blot analysis of HMGB1 in naïve and
transplanted wildtype and RIPK3-/- hearts. Separate bands represent the amount of
immunogenic (upper band) or oxidized forms (lower band) of HMGB1. Data shown
is representative of five transplanted grafts. B) Densitometry analysis of
immunogenic and oxidized HMGB1 (n=5, *: p<0.05). β-actin was used as a loading
control and quantitation reference. C) Paraffin fixed sections were stained for total
HMGB1in both wild type and RIPK3-/- hearts. Areas of HMGB1 being released into
the cytoplasm and in nuclei undergoing harryorrhexis are indicated by arrows. D)
cDNA was isolated from heart grafts collected 12 days following heart
transplantation and analysed by RT-qpPCR for chemokine expression. Values are
representative of five separate experiments.
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3.10 RIPK3 deficiency in heart allografts prolongs graft
survival after transplantation following sirolimus treatment
To determine if RIPK1/3 mediated necroptotic death could influence cardiac transplant
survival, we performed heterotopic transplantation of wildtype C57BL/6 or B6 RIPK3-/donor hearts into fully MHC mismatched recipient BALB/c mice. As shown in Figure
14A, without immunosuppressive treatment, RIPK3 null heart grafts have similar
survival times compared to wildtype grafts (10+0.8 days in wildtype vs. 10.3+0.5 days in
RIPK3-/-, n=4). However, treatment with sirolimus (1mg/kg) from surgical day 0 to day 9
extended the survival time of wildtype grafts to 24 + 2.6 days and RIPK3-/- grafts to 95 +
5.8 days (n=4, P=0.011). As shown in Figure 14B, naïve C57BL/6 hearts do not appear
histologically different from naïve RIPK3-/- hearts, but wildtype heart grafts show severe
lymphocyte infiltration and vasculopathy at rejection day compared with RIPK3-/- grafts
collected on day 40. RIPK3 was also detected in the endothelium and cardiac myocytes
of naïve wild type hearts, but not RIPK3-/- hearts, by immunohistochemistry. This data
indicates the absence of RIPK3 in heart grafts can greatly prolong graft survival,
suggesting that RIPK3 mediated necroptotic death has a deleterious effect on heart graft
survival.
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Figure 14 – RIPK3 deletion in donor grafts induced long term graft survival
Wildtype C57BL/6 or B6 RIPK3-/- donor hearts were transplanted into BALB/c
recipients. Sirolimus (1mg/kg) was given daily from operative day 0 to postoperative day 9. Graft survival was monitored daily by palpitation. Significant drop
or cessation of pulsation is considered as graft rejection. A) Survival curve of
wildtype C57BL/6 and RIPK3-/- donor heart grafts in BALB/c mice was obtained
from two repeated experiments with and without sirolimus treatment (n=4, *: p <
0.05, Log rank test). B) RIPK3 detection in heart grafts and H&E comparison of
wildtype and RIPK3-/- grafts. Heart grafts were collected from wild type recipients
24 days after transplantation and RIPK3-/- graft recipients 40 days after
transplantation and fixed by formalin before H&E staining or
immunohistochemistry analysis by anti-RIPK3 (Abcam).
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3.11 CD40 costimulatory blockade does not extend RIPK3
null graft survival following cardiac transplantation
Cardiac allograft transplantation was again performed using wildtype and RIPK3-/- donor
grafts with a single treatment of MR1 (200ug) one day before transplantation. In both
wildtype and RIPK3-/- grafts, rejection began at post-operative day 20 and is shown
histologically in Figure 15A. Pathological scoring during rejection revealed no significant
differences in endothelial damage, necrosis, infiltrate or myocyte damage (n=2) between
wildtype and RIPK3-/- grafts, as shown in Figure 15B.
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Figure 15 – RIPK3 deletion does not protect heart grafts following CD40
costimulatory blockade
Wildtype C57BL/6 or B6 RIPK3-/- donor hearts were transplanted into BALB/c recipients.
Anti-CD154 (200ug) was given daily from operative day 0 to post-operative day 9. Graft
survival was monitored daily by palpitation. Significant drop or cessation of pulsation is
considered as graft rejection. A) Wild type and RIPK3-/- grafts were examined using H&E
staining and confocal microscopy (400X) following rejection after day 20. B) Blinded
pathological scoring of rejected grafts for endothelial damage, necrosis, infiltrate and
myocyte damage (n=2, p > 0.05).
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Chapter 4

4

Discussion

4.1 Summary of this study
In this study, we isolated, immortalized and characterized a new murine MVEC cell line
for in vitro experimental use (Figure 5). We have shown at the mRNA and protein level
that RIPK3 can be upregulated by TNFα and that TNFR1 can be upregulated by both
TNFα and/or IFNγ in MVECs (Figure 6). Necroptotic death and subsequent danger
molecule HMGB1 release were also observed in wildtype MVECs under anti-apoptotic
conditions, which could be significantly attenuated following pharmacological RIPK1
inhibition or RIPK3 knockout (Figures 8 and 11). We also observed that RIPK3 null
MVECs underwent apoptosis following super-physiological treatment of TNFα, which
could be partially recovered by caspase inhibition (Figure 10). Following cardiac
allograft transplantation, RIPK3 null donor grafts survived significantly longer following
sirolimus treatment than wild type donor grafts (Figure 14). Following transplantation,
RIPK3 null grafts showed significantly less host immune infiltration and necrosis
compared with wild type grafts while maintaining similar levels of apoptosis (Figure 12).
Lastly, protein levels of danger molecule HMGB1 were attenuated in RIPK3 null
allografts shortly following transplantation (Figure 13). The ability of
immunosuppression to provide rejection protection is dependent on the cell death pattern
of the graft following transplantation. We suggest that targeting proteins RIPK1 or
RIPK3 in heart grafts may be beneficial in future transplantation therapies.
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4.2 Inflammatory injury, cellular rejection and cell death
In clinical cardiac transplantation, injury and inflammation can result in delay or loss of
graft function and reduced survival rates following transplantation. Mechanisms of
injury, such as IRI, commence early in the transplantation procedure, while others
continue throughout the life of the graft, such as chronic cellular rejection and GVD.
These mechanisms of injury initiate different forms of cell death in graft parenchymal
and endothelial cells, including apoptosis, autophagy and necrosis, which may influence
the outcome of the graft through inflammatory sequelae.

Cardiac transplantation invariably results in damage to the transplanted organ beginning
with organ procurement, storage, surgical manipulation, ischemic time and reperfusion
injury. These necessary procedures can often influence long-term graft survival through
early up-regulation of alloantigens and cell adhesion molecules, leading to accelerated
allorecognition104. IRI can result in apoptotic, autophagic and necrotic cell death,
subsequently initiating host immune responses and the promotion of antibody and cell
mediated rejection86, 105-107. These various forms of cell death potentially have important
implications on the severity of the immune responses following transplantation and can
greatly influence early and chronic survival of the graft.

Following IRI, cardiac grafts are susceptible to ACR, which constitutes one of the most
frequent causes of profound graft tissue damage within the first year after transplantation.
Acute injury is often an adaptive immune response initiated following the maturation of
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recipient CD4+ helper T cells, CD8+ cytotoxic T cells and B lymphocytes. These cell
types can attack the graft through direct or indirect allorecognition pathways.

Chronic cardiac allograft rejection presents as GVD, a severe, diffuse vascular intimal
hyperplasia with eventual stenosis of the vascular wall resulting in compromised vascular
flow and ischemia. It is unclear whether the incidence of ACR can affect long term graft
survival by accelerating GVD through early allorecognition. Many studies have
positively correlated ACR and GVD108-110, however, others have failed to find a direct
correlation between biopsy-confirmed acute rejection and GVD111-113. Instead, GVD
seems to result from any cellular insult including IRI9, 12-14, indirect allorecognition by
CD4+ T cells17 and cytokine release15, 16.

In clinical transplantation, the short-term success rate of allografts has steadily improved
over the decades while long-term graft attrition has remained constant1, 114-116.
Improvements in short-term transplant success can be attributed to improved
immunosuppressive management of acute rejection episodes, organ preservation, donor
selection, biopsy management and techniques, and diagnosis and management of
infection. However, despite our increased knowledge of immunobiology and improved
immunosuppressive therapies, long-term functional survival times of cardiac allografts
remains stagnant and thus transplantation has remained a treatment, rather than a cure, for
devastating cardiac events. In this study, we attempt to augment cell death in the donor
graft through inhibition or deletion of the RIPK proteins, which are critical in the
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initiation of necroptotis, a cell death pathway that enhances rejection initiating immune
responses.

Apoptotic cell death has been extensively studied in cancer, infectious disease,
autoimmune disease and transplantation117, 118. Apoptosis leads to the formation of
annexin-V positive apoptotic bodies that sequester cellular contents and are rapidly
eliminated via phagocytosis by other cells with minimal inflammation117, 118. This process
is initiated following the activation of caspases, a series of highly regulated endogenous
cysteine proteases. Some caspases are pro-inflammatory, such as caspase-1, which
localizes in inflammasomes to process IL-1β and IL18119, while others require death
receptor engagement. The death receptor pathway is induced by TNFR super-family
members (TNFR1, Fas, TRAIL) and requires the activation of caspase 8 to initiate
apoptosis. Traditionally, apoptosis was thought to be a neutral factor in transplantation
due to its non-immunogenic properties. However, recent studies have proved otherwise.
Endothelial cell apoptosis has been shown to be an immunoregulatory process that is
important in GVD related intimal remodelling120, 121, while the release of “find me” and
“eat me” signals by apoptotic cells has been shown to recruit macrophages and
monocytes122-124. In addition, apoptotic cells not cleared by the immune system may
undergo secondary necrosis with subsequent plasma membrane permeation and release of
CDAMPS, similar to necrosis or necroptosis117.

Necrosis was traditionally regarded as an unregulated means of cell death as a result of
unexpected cellular stresses. Recently, it has been observed that the death receptors
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TNFR1 or Fas, when engaged, can elicit necrosis as well as apoptosis64, 125, 126,
suggesting necrosis can also be regulated by signal transduction pathways. This regulated
form of caspase-dependent necrosis has now been termed necroptosis and is controlled by
RIPK1 and RIPK359, 69, 80, 126. Necroptosis is characterized by the same morphological
features as unregulated necrotic death, including early loss of plasma membrane integrity
and release of cytoplasmic contents127. These contents, such as immunogenic CDAMPS,
can bind to immune cell receptors and initiate powerful immune responses75.

In this study, necroptosis was induced in vitro using TNFα. TNFα is a proinflammatory
cytokine produced by graft infiltrating cells, endothelial cells, and cardiac myocytes.
TNFα quickly increases in cardiac grafts after transplantation43, 45 and has been shown to
be an important contributor of heart graft rejection44-46, 48, 128. In addition, TNFα blockade
or TNFR deficiency has been shown to prolong cardiac graft survival in several animal
models44, 46, 47. TNFα induces death through TNFR1 but promotes pro-inflammatory
responses through TNFR2129.

Interestingly, myocardium in human donor heart grafts can modulate TNFR expression
following rejection related injury by radically down-regulating TNFR1 and up-regulating
TNFR2 surface expression following heart transplantation48. Conversely, human and
murine endothelial cells do not undergo radical changes in TNFR1 expression patterns
before and post transplantation48 and therefore are susceptible to TNFα induced cell
death. As the first barrier between graft and host, MVEC’s undergoing early necroptotic
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death may promote cardiac graft inflammation and subsequently augment rejection
responses. Here we have shown that inhibition of caspase function enhanced necrotic cell
death and the release of HMGB1 in endothelial cells and inhibition of RIPK1 or RIPK3
function attenuated necroptotic death (Figure 8 A-C) and subsequent danger molecule
HMGB1 release (Figure 11A&B). RIPK3 deficiency in donor heart allografts prevented
endothelial necrotic death, HMGB1 release, and substantially prolonged graft survival
after short-term sirolimus treatment. This study suggests that RIPK1/3-mediated
necroptosis contributes to inflammatory injury in cardiac allografts and that RIPK1 and
RIPK3 are important therapeutic targets to induce long term graft survival.

4.3 The pattern of cell death can be differentiated using
pharmacological inhibitors or genetic modification
In recent years, our understanding of cell death has expanded beyond apoptosis,
autophagy and necrosis and now includes regulated necrosis which comprises RIPK
mediated necroptosis, pyronecrosis, excitotoxicity, pyroptosis, parthanatos, NETosis,
entosis, ferroptosis, anoikis, lysosomal membrane permeabilization, Wallerian
degeneration and heat-stroke-induced regulated necrosis130. Consequently, various forms
of cell death detection have arisen to differentiate between cell death forms. These
methods include quality of DNA fragmentation, morphology, cell viability, caspase
activation, PARP1 cleavage, and labeling with Annexin or PI, among others. However,
these methods alone are often non-definitive and often require conjunction with
inflammatory markers and the use of pathway-specific pharmalogical inhibitors, RNA
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knockdown or animal models with genetic deletion to confirm a specific cell death
pathway75, 131.

In this study, PI labeling was used in vitro to identify necroptotic cell death, a method
previously used in many studies49, 50, 60, 65, 86, 132, 133, while others have used annexin-V
labeling to detect necroptotic death 69, 133-135. PI is an intercalating agent and binds to
DNA inside the nucleus of cells. This requires the loss of plasma membrane integrity as
PI cannot permeate healthy cell membranes. Annexin V binds phosphatidylserine,
making it a useful marker for detecting apoptosis following the apoptotic plasma
membrane translocation of phospholipids136. Sawai and colleagues, using a human
monocyte leukemia cell line, U-937, have previously shown that necroptotic cells can
label as annexin V positive / PI negative, annexin V negative / PI positive, or annexin V
positive / PI positive137. However, their data only shows PI positive labeling in antiapoptotic conditions after zVAD-fmk treatment, an important pro-necroptotic condition.
Furthermore, their conclusion that necroptotic cells could label as annexin V positive / PI
negative was based on the observation that Nec-1 could recover annexin V positive / PI
negative cell death. Although it is known that PI positivity can result from secondary
necrosis following apoptosis137, PI labeling while augmenting cell death using zVADfmk, Nec-1 and RIPK3-/- MVECs in conjunction with the release of the inflammatory
marker HMGB1 is sufficient evidence of necroptosis.
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Necroptosis becomes the predominant form of cell death when caspase 8-mediated
apoptotic pathways are blocked and can be reverted to apoptosis in the presence of RIPK
inhibition64, 138, 139. Hence, caspase-8 is not only an inducer of apoptosis, but also an
inhibitor of necroptosis as it has been observed that caspase-8 deficiency leads to
unregulated necroptosis in the yolk sack vessels of developing embryos, resulting in early
embryonic lethality140-142. Therefore, blocking apoptotic regulators, particularly caspase
8, may not benefit heart graft survival as it may enhance necroptosis and worsen
inflammatory injury in the graft. Alternatively, targeting RIPK proteins would inhibit
necroptosis and thus minimize graft injury. Vercammen and colleagues showed the
profound effects of zVAD-fmk in L929 fibroblasts on necroptotic death. In their
experiments, the half-maximal dose of TNFα needed to induce necroptosis was decreased
by a factor of 1000 in the presence of zVAD-fmk and exogenous TNFα over TNFα
alone50. Since these findings were published, zVAD-fmk has been used in several studies
to induce necroptosis54, 63, 69, 84, 135, 143. This mechanism was discovered to be prominent
in mouse L929 fibroblasts49 and was confirmed in this study (Figure 7).

4.4 HMGB1 as a marker for necroptosis and inflammation
Necrosis results in inflammatory sequelae mediated by the release of cell contents
including HMGB1, heat-shock proteins, histones, uric acid, RNA, and DNA, all of which
can trigger inflammatory reactions74-76. HMGB1, which augments expression of
chemokines and cytokines that attract and activate diverse immune cells through binding
on its receptors TLR-2 or -4, has been shown to participate in early heart injury and
further augments adaptive immune responses during graft rejection75, 76, 144. Importantly,
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HMGB1 is mainly released from necrotic, but not apoptotic or late apoptotic cells, which
results in pro-inflammatory responses74. In our study, HMGB1 was used to confirm
necroptotic cell death in conjunction with PI labeling, which may bind late apoptotic and
secondary necrotic cells. Indeed, we found that necroptosis-induced HMGB1 release was
substantially inhibited in RIPK3 deficient MVECs or by inhibiting RIPK1 with Nec-1
(Figure 11A&B). This finding was further supported by the results of our in vivo study
where the release of HMGB1was inhibited in RIPK3-/- heart grafts compared with wild
type heart grafts (Figure 13A&B). However, a challenge arose in finding a method of
quantifying necrotic cell death in vivo to correlate cell death and HMGB1 release in heart
grafts. Previous studies have relied on microscopy and pathological scoring, which are
susceptible to high degrees of inter-observer variability. To address this, we modified a
protocol of ethidium homodimer perfusion into a mouse kidney92 for application in a
heterotopic heart. Ethidium homodimer, similar to PI, binds DNA after cell membrane
rupture. In the heterotopic heart, ethidium homodimer staining of the endotheilium and
cardiomyocytes indicated the level of vascular damage, leakiness and myocyte necrosis.
Consequently, we found that ethidium homodimer staining and lymphocyte infiltration
were significantly greater in wild type mice 12 days after transplantation than RIPK3-/heart grafts (Figure 12A-C). In addition, immunohistochemistry in heart graft sections
revealed increased HMGB1 staining in cellular nuclei undergoing karyorrhexis and in the
cytoplasm of cardiomyocytes (Figure13C). Finally, compared with wildtype donor grafts,
RIPK3 deficiency in donor heart grafts induced long term graft survival following shortterm sirolimus treatment (Figure 14A). These data suggest that RIPK3-mediated
necroptosis contributes to the release of the danger molecule HMGB1 and subsequently
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enhances inflammatory injury in heart allografts. Hence, RIPK1/3-mediated necroptosis
and subsequent inflammatory responses play a reciprocal role for heart graft rejection.
Inhibiting the feedback loop of TNFα, RIPK, HMGB1 and infiltrating immune cells may
prevent graft injury and promote long term graft survival.

4.5 HMGB1 subtypes influence immune responses
Previous research suggests that different forms of HMGB1 can be released during cell
death103, 145. The active form of HMGB1 released from necrotic cells has an
immunogenic function through TLR interaction, whereas cells undergoing apoptosis
release a tolerogenic form of HMGB1whose stimulatory function is neutralized after
oxidization103. More recently, a third form of HMGB1, all-thiol-HMGB1, has been
shown to exist and acts as a chemoattractant to recruit leukocytes. In our study, wild type
heart grafts 12 days after transplantation have much higher levels of the active form of
HMGB1 than RIPK3-/- grafts (Figure 13A&B). Binding of this form of HMGB1 to TLR4 and RAGE receptors promotes T cell, macrophage and DC maturation, exacerbating
cellular mediated graft rejection. There were no differences in levels of the oxidized form
of HMGB1 between wild type and RIPK3 null heart grafts, indicating that apoptosis in
heart grafts was not altered by RIPK3 deficiency. This finding was supported by heart
tissue TUNEL staining, which showed no significant differences in apoptotic area in
heart grafts compared wild type and RIPK3-/- mice (Figure 13A&E). However, the
presence of oxidized HMGB1 in heart grafts contrasted the HMGB1 profile in MVECs in
vitro, where only the immunogenic form of HMGB1 was detected by western blot
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following MVEC necroptosis. In this instance, the oxidized form of HMGB1 seen in vivo
may have originated from host infiltrating cells146 or other heart cells. The third form of
HMGB1 has yet to be identified via western blot but likely contributed to graft rejection
via a chemotactic funciton145. Additionally, no significant changes were seen in the
expression of chemokines between wild type and RIPK3-/- grafts. Nonetheless, both our
in vitro and in vivo results further support the notion that necroptosis results in the release
of danger molecule HMGB1 and augments graft rejection in transplantation. In contrast,
apoptosis will result in decreased danger molecule release and minimize cell deathinduced inflammatory responses in heart graft. Hence, programmed apoptotic cell death,
rather than necroptotic cell death, may be beneficial for heart graft survival.

4.6 Cardiac allograft survival and immunosuppressive
management
In clinical transplantation, proper immunosuppressive management is critical in
preventing both acute and chronic rejection. Several immunosuppressive regimens
currently exist in the clinic, many of which inhibit T cell survival, activation and clonal
expansion. This outcome is achieved by targeting molecular pathways involved in T cell
recognition of foreign antigens, costimulatory pathway activation and the production of
IL-2. Clinically, drugs such as tacrolimus, sirolimus and thymoglobulin are used to
prevent T cell proliferation, while costimulatory blockades have been successful in preclinical trials but have not yet been used clinically.
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In this study, wild type C57BL/6 and RIPK3-/- heterotopic donor cardiac grafts were
transplanted into recipient Balb/c mice followed by short-term sirolimus treatment. Using
this model, we observed significant improvements in graft survival in both wild type and
RIPK3-/- donor hearts compared with untreated grafts. Furthermore, we observed
significant increases in graft survival time, cellular necrosis and lymphocyte
inflammation in RIPK3-/- grafts compared with sirolimus treated wild type grafts (Figure
14A&B). This data provides evidence that the efficacy of immunosuppression is
dependent on the pattern of cell death in the graft and the removal of immunogenic
necroptosis benefits heart graft survival.

However, it is possible that the deletion of RIPK3 in donor grafts may affect other cell
death pathways, such as apoptosis and autophagy. Indeed, we observed significant
resistance of RIPK3-/- MVECs to apoptosis following hTNFα treatment (Figure 10).
Furthermore, augmentation of cell death pathways may be further influenced by the
chosen method of immunosuppression. Previous groups have reported the induction of
cellular autophagy following sirolimus treatment in many mouse models147-149. The
induction of autophagy by sirolimus could potentially benefit long-term graph survival,
sparing the graft from apoptotic and immunogenic necroptotic death. Therefore, the
beneficial effect of sirolimus in heart cells needs further investigation, despite only
treating with sirolimus for 9 days after transplantation. Alternatively, we transplanted
wild type and RIPK3-/- hearts into Balb/c recipients using anti-CD154 costimulatory
blockade to inhibit T cell responses. A sub-therapeutic dose of 200ug anti-CD154
antibody was used since Zhang and colleagues have previously shown a 250ug single-
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dose treatment of anti-CD154 induces a 40% acceptance rate after 100 days in wild type
grafts150. However, RIPK3-/- grafts treated with 200ug of anti-CD154 showed no
differences in survival or lymphocyte infiltration (Figure 15A&B). Future studies should
use a 250ug dose to compare the 40% wild type acceptance rate to that of RIPK3-/- grafts.

These results indicate that the method of immunosuppression may be important during
graft-targeted therapy. However, retrospective consideration of the tolerance inducing
mechanism of our RIPK3-/- model versus that of anti-CD154 therapy leads us to believe
that the tolerance inducing mechanism in each model is mutually exclusive. As
mentioned previously, the CD40/CD154 interaction has important implications in plasma
cell antibody type switching and absence of CD40 or inhibition of CD154 results in
hyper-IgM syndrome28. As RIPK3 mediated necroptosis is initiated by TNFα or Fas
binding to cellular receptors, disruption of immunoglobulin class switching should have
no effect on the survival of RIPK3-/- grafts. Although CD40/CD154 is known to affect T
cell activation, the mechanism is indirect via the upregulation of CD80 or CD86 on APCs
and may not greatly affect TNFα production by CD4+ T cells. Furthermore, anti-CD154
treatment alone is known to induce only acute rejection protection, and not chronic
rejection protection, in heart allograft models30, 151. Instead, anti-CD154 treatment is
recommended to be used in conjunction with sirolimus to promote long-term tolerance
and prevent chronic rejection152. In either model, robust cellular and humoral immune
responses quickly cause cell death within the graft. Immunosuppressive therapies
currently prevent early graft rejection, but chronic rejection still can occur through the
slow and steady destruction of heart cells over time. Therefore, the RIPK1/RIPK3
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mediated death pathway is more relevant in chronic, rather than acute, rejection. Future
studies using treatment with CTLA4Ig, which directly blocks CD28 activation on T cells,
may have be a more effective method of demonstrating the advantage of RIPK3-/- grafts.
Nonetheless, anti-CD154 and CTLA4Ig treatment have not been successfully transferred
into clinical therapy. This study may provide a sound rationale that using clinically
relevant drugs such as sirolimus, tacrolimus, or thymoglobulin in conjunction with donorspecific anti-cell death therapy for future patient treatment.

4.7 Conclusion
In this study we have demonstrated that RIPK3 and TNFR1 expression on MVECs can
be regulated by TNFα and IFNγ. We have shown for the first time in MVECs that
caspase 8 plays a protective role against RIPK1 and RIPK3 mediated necroptosis as
blockade of caspase 8 exacerbates, while inhibition of RIPK1 or RIPK3 abrogates,
necroptotic death. We have also shown that danger molecule HMGB1 release correlates
with necroptotic cell death in MVECs. Furthermore, following heterotopic heart
transplantation, deletion of RIPK3 in donor hearts ameliorates necrotic death,
inflammation and HMGB1 release in the donor graft, leading to prolonged survival.
Inhibition of RIPK1 or RIPK3 in transplant patients may therefore protect the donor heart
graft from necroptosis, decreasing graft immune infiltration and the release of
proinflammatory danger signals that lead to chronic allograft injury.
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4.8 Future direction
We recommend that future studies explore the clinical importance of necroptosis in
transplantation through the use of clinically relevant immunosuppressive therapies such
that this treatment may be brought from bench to bedside. This includes developing
methods of graft specific targeting of proteins RIPK1 and RIPK3, perhaps during donorto-recipient transfer, and determining the effect of RIPK1/RIPK3 inhibition on other
forms of cell death following immunosuppression.
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